Afeyan Noubar's Form 4 filing
Moderna, Inc. (MRNA) · filed May 13, 2022
- Accession no.
- 0000899243-22-018043
- Filed
- May 13, 2022
- Trade date
- May 11-13, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 9 non-derivative transactions. Open-market sales total $40.9M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Afeyan NoubarCIK 0001222012 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 11, 2022 | Common Stock | SSaleDisposed | −10,000 | $130.74 | −$1,307,400 | 2,229,673 | Direct | |
| May 12, 2022 | Common Stock | SSaleDisposed | −75,944 | $129.39F2 | −$9,826,394.16 | 6,040,713 | Indirect | |
| May 12, 2022 | Common Stock | SSaleDisposed | −41,182 | $130.08F4 | −$5,356,954.56 | 5,999,531 | Indirect | |
| May 12, 2022 | Common Stock | SSaleDisposed | −51,256 | $131.45F5 | −$6,737,601.2 | 5,948,275 | Indirect | |
| May 12, 2022 | Common Stock | SSaleDisposed | −31,618 | $132.22F6 | −$4,180,531.96 | 5,916,657 | Indirect | |
| May 13, 2022 | Common Stock | SSaleDisposed | −25,433 | $133.11F7 | −$3,385,386.63 | 5,891,224 | Indirect | |
| May 13, 2022 | Common Stock | SSaleDisposed | −24,567 | $134.04F8 | −$3,292,960.68 | 5,866,657 | Indirect | |
| May 13, 2022 | Common Stock | SSaleDisposed | −49,900 | $135.37F9 | −$6,754,963 | 5,816,757 | Indirect | |
| May 13, 2022 | Common Stock | SSaleDisposed | −100 | $136.00 | −$13,600 | 5,816,657 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Represents (i) 63,512 shares sold by Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and (ii) 12,432 shares sold by Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"). The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $129.00 to $129.93, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Following the reported transactions, 3,212,827 shares are held directly by Flagship Fund IV and 2,827,886 shares are held directly by Flagship Fund IV-Rx.
Referenced by the price of 1 transaction in Table I.
- F4
Represents (i) 34,589 shares sold by Flagship Fund IV and (ii) 6,593 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.00 to $130.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Following the reported transactions, 3,178,238 shares are held directly by Flagship Fund IV and 2,821,293 shares are held directly by Flagship Fund IV-Rx.
Referenced by the price of 1 transaction in Table I.
- F5
Represents (i) 43,035 shares sold by Flagship Fund IV and (ii) 8,221 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.00 to $131.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Following the reported transactions, 3,135,203 shares are held directly by Flagship Fund IV and 2,813,072 shares are held directly by Flagship Fund IV-Rx.
Referenced by the price of 1 transaction in Table I.
- F6
Represents (i) 26,546 shares sold by Flagship Fund IV and (ii) 5,072 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.00 to $132.62, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Following the reported transactions, 3,108,657 shares are held directly by Flagship Fund IV and 2,808,000 shares are held directly by Flagship Fund IV-Rx.
Referenced by the price of 1 transaction in Table I.
- F7
Represents (i) 21,250 shares sold by Flagship Fund IV and (ii) 4,183 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $133.00 to $133.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Following the reported transactions, 3,087,407 shares are held directly by Flagship Fund IV and 2,803,817 shares are held directly by Flagship Fund IV-Rx.
Referenced by the price of 1 transaction in Table I.
- F8
Represents (i) 20,621 shares sold by Flagship Fund IV and (ii) 3,946 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $134.00 to $134.27, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Following the reported transactions, 3,066,786 shares are held directly by Flagship Fund IV and 2,799,871 shares are held directly by Flagship Fund IV-Rx.
Referenced by the price of 1 transaction in Table I.
- F9
Represents (i) 41,885 shares sold by Flagship Fund IV and (ii) 8,015 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.00 to $135.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Following the reported transactions, 3,024,901 shares are held directly by Flagship Fund IV and 2,791,856 shares are held directly by Flagship Fund IV-Rx.
Referenced by the price of 1 transaction in Table I.